As of 2024-12-15, the Relative Valuation of Nektar Therapeutics (NKTR) is (22.31) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.01 USD, the upside of Nektar Therapeutics based on Relative Valuation is -2308.7%.
The range of the Relative Valuation is (15.82) - (24.74) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 27.1x | 24.0x |
| Forward P/E multiples | 17.3x - 27.5x | 24.9x |
| Fair Price | (15.82) - (24.74) | (22.31) |
| Upside | -1666.4% - -2549.9% | -2308.7% |
| Date | P/E |
| 2024-12-04 | -1.12 |
| 2024-12-03 | -1.17 |
| 2024-12-02 | -1.29 |
| 2024-11-29 | -1.25 |
| 2024-11-27 | -1.24 |
| 2024-11-26 | -1.17 |
| 2024-11-25 | -1.19 |
| 2024-11-22 | -1.15 |
| 2024-11-21 | -1.11 |
| 2024-11-20 | -1.10 |
| 2024-11-19 | -1.13 |
| 2024-11-18 | -1.13 |
| 2024-11-15 | -1.17 |
| 2024-11-14 | -1.28 |
| 2024-11-13 | -1.40 |
| 2024-11-12 | -1.44 |
| 2024-11-11 | -1.50 |
| 2024-11-08 | -1.53 |
| 2024-11-07 | -1.50 |
| 2024-11-06 | -1.52 |
| 2024-11-05 | -1.53 |
| 2024-11-04 | -1.46 |
| 2024-11-01 | -1.35 |
| 2024-10-31 | -1.30 |
| 2024-10-30 | -1.37 |
| 2024-10-29 | -1.39 |
| 2024-10-28 | -1.49 |
| 2024-10-25 | -1.45 |
| 2024-10-24 | -1.48 |
| 2024-10-23 | -1.55 |
| 2024-10-22 | -1.58 |
| 2024-10-21 | -1.52 |
| 2024-10-18 | -1.55 |
| 2024-10-17 | -1.59 |
| 2024-10-16 | -1.51 |
| 2024-10-15 | -1.41 |
| 2024-10-14 | -1.45 |
| 2024-10-11 | -1.49 |
| 2024-10-10 | -1.41 |
| 2024-10-09 | -1.42 |
| 2024-10-08 | -1.42 |
| 2024-10-07 | -1.40 |
| 2024-10-04 | -1.45 |
| 2024-10-03 | -1.42 |
| 2024-10-02 | -1.46 |
| 2024-10-01 | -1.42 |
| 2024-09-30 | -1.42 |
| 2024-09-27 | -1.28 |
| 2024-09-26 | -1.22 |
| 2024-09-25 | -1.27 |